Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

NMTC vs INM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

INM Captures Overall Composite Edge (35.6 SELL vs 45.5 HOLD), While NMTC Leads 4–2 on Growth & Valuation Pillars

INM Overall Winner 6-Pillar Tally: NMTC 4 – 2 INM Matrix Metrics: NMTC 4 – 3 INM

As of Nov 20, 2026, InMed Pharmaceuticals Inc. Common Shares (INM) captures the overall head-to-head institutional edge over NeuroOne Medical Technologies Corporation (NMTC) on higher Unified Composite conviction (35.6/100 SELL vs. 45.5/100 HOLD) after splitting the core matrix 3–4 (led by Profitability & Quality, R&D & Supply-Chain Moat), while NMTC wins 4–2 across the 6-pillar growth and valuation breakdown. NMTC trades at $0.65 (N/M Forward P/E, -63.4% operating margin) versus INM at $15.56 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While NMTC currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. INM 35.6/100 SELL), INM captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -63.4% operating margin) and revenue trajectory (-26.2% vs. +16.3% YoY).
  • Technical & Structure Timing Caution: NMTC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile INM trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 99.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NMTC vs INM
NMTC NASDAQ
NeuroOne Medical Technologies Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$0.65
-3.38% 1D
Market Cap $6.1M
TTM Revenue $12M
Forward P/E N/M
Beta / 30D Vol 1.55β · 105% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 60.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -28.4%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $0.83 · SMA50: $1.03
INM NASDAQ Head-to-Head Winner
InMed Pharmaceuticals Inc. Common Shares
Pharmaceutical Preparations
$15.56
+17.79% 1D
Market Cap $7.3M
TTM Revenue $4.9M
Forward P/E N/M
Beta / 30D Vol -20.85β · 2208% Vol
Unified Composite Score
35.6 / 100 SELL
Tech 15.0 Fund 32.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (37.6% over 20 days), RSI 99
RSI-14: 99.3 · SMA20: $2.77 · SMA50: $1.91

6-Pillar Scorecard Institutional Category Breakdown (NMTC 4 – 2 INM)

Columns: Metric · NMTC · INM
1. Valuation Multiples NMTC
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.3x 0.5x
2. Growth & Scale NMTC
Revenue Growth (YoY) +16.3% -26.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $12M $4.9M
Market Cap $6.1M $7.3M
3. Profitability & Quality INM
Gross Margin 23.0% 34.5%
Operating Margin -63.4% 0.0%
Net Profit Margin -59.7% 0.0%
Return on Equity (ROE) -124.7% -222.1%
4. Balance Sheet & Cash Flow NMTC
Cash Generation (TTM) -$7.6M -$7.5M
Cash Flow Margin -60.7% N/A
Net Cash / Leverage $2.6M Net Cash $4.7M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NMTC
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat INM
OpEx & R&D Intensity N/A 34.5% of Rev ($1.7M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NMTC (4) vs INM (3)
Institutional Metric NMTC INM Criterion Row Edge
Market Capitalization
Scale
$6.1M $7.3M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+16.3% -26.2% Higher Growth NMTC
Operating Margin (TTM)
Profitability
-63.4% 0.0% Higher Margin INM
Net Profit Margin
Profitability
-59.7% 0.0% Higher Margin INM
Return on Equity (ROE)
Capital Efficiency
-124.7% -222.1% Higher ROE NMTC
52-Week Range Position
Momentum
2% ($1–$5) 94% ($1–$16) Stronger Trend INM
Beta / 30D Volatility
Risk Regime
1.55β · 105% Vol -20.85β · 2208% Vol Lower Realized Risk NMTC
Unified Institutional Score
Composite Signal
45.5 / 100 (HOLD) 35.6 / 100 (SELL) Higher Composite NMTC
Trailing 12M Revenue (USD)
Operating Scale
$12M $4.9M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
23.0% 34.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev N/M PEG · 0.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.6M ($2.6M Net Cash) -$7.5M ($4.7M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon INM +1088.53 pp
NMTC: -18.61% · INM: +1069.92%
3M Horizon INM +1047.2 pp
NMTC: -43.65% · INM: +1003.55%
6M Horizon INM +2375.38 pp
NMTC: -81.53% · INM: +2293.85%
1Y Horizon INM +1125.54 pp
NMTC: +39.5% · INM: +1165.04%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NMTC Revenue INM Revenue NMTC Op. Margin INM Op. Margin Margin Leader
FY2012 $0M N/A -1491.1% N/A NMTC
FY2013 $0M N/A -2009.0% N/A NMTC
FY2014 $0M N/A -4646.1% N/A NMTC
FY2021 $0M $0M -5735.9% -535.9% INM
FY2022 $0M $0M -5860.2% -1361.9% INM
FY2023 $0M $0M -612.3% -192.2% INM
FY2024 $0M $0M -344.3% -166.9% INM
FY2025 $10M $0M -46.5% -165.1% NMTC

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NMTC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NMTC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
INM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact INM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NMTC Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.1M market capitalization and -63.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
INM Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $7.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment 34.5% of Rev ($1.7M)
90D Engineering Disclosures 0 Published

Investor FAQ NMTC vs INM Key Questions & Quantitative Answers

As of Nov 20, 2026, InMed Pharmaceuticals Inc. Common Shares (INM) captures the overall head-to-head institutional edge over NeuroOne Medical Technologies Corporation (NMTC) on higher Unified Composite conviction (35.6/100 SELL vs. 45.5/100 HOLD) after splitting the core matrix 3–4 (led by Profitability & Quality, R&D & Supply-Chain Moat), while NMTC wins 4–2 across the 6-pillar growth and valuation breakdown. NMTC trades at $0.65 (N/M Forward P/E, -63.4% operating margin) versus INM at $15.56 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While NMTC currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. INM 35.6/100 SELL), INM captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -63.4% operating margin) and revenue trajectory (-26.2% vs. +16.3% YoY). Technical & Structure Timing Caution: NMTC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile INM trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 99.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NMTC leads the Growth & Scale pillar: NMTC posts +16.3% YoY revenue growth and +0.0% YoY earnings growth on $12M TTM revenue (23.0% gross margin, -63.4% operating margin), compared with INM at -26.2% YoY revenue growth and +0.0% YoY earnings growth on $4.9M TTM revenue (34.5% gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2012 to FY2025), NMTC cumulative revenue shifted N/A while INM shifted N/A. In operating R&D and SG&A reinvestment, NMTC deploys N/A (0 90-day corporate R&D disclosures) versus 34.5% of Rev ($1.7M) (0 disclosures) for INM.

NMTC screens cheaper on headline valuation multiples. NMTC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-60.7% FCF margin), whereas INM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NMTC (-124.7% ROE) versus INM (-222.1% ROE) capital efficiency.

In options market volatility and institutional positioning, NMTC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 105% Vol realized risk). By comparison, INM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-20.85β · 2208% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.